From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: A 6-month, multicenter, open-label tolerability switch study

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 16, 2011, Pages 2425-2431

  Rossi, Gemma Caterina Maria ^a   Pasinetti, Gian Maria ^b   Sandolo, Francesco ^c   Bordin, Marco ^a   Bianchi, Paolo Emilio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Clinica Beato Palazzolo   (Italy)

^c NONE   (Italy)

Author keywords

brinzolamide timolol fixed combination; efficacy; glaucoma; ocular surface; tolerability

Indexed keywords

BRINZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; FLUORESCEIN;

AGED; ARTICLE; BLURRED VISION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; QUALITY OF LIFE; RATING SCALE; SYMPTOM; SYSTEMIC DISEASE; TEAR FILM;

AGED; ANTIHYPERTENSIVE AGENTS; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; QUALITY OF LIFE; QUESTIONNAIRES; SULFONAMIDES; THIAZINES; THIOPHENES; TIMOLOL;

EID: 80054058311     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.589384     Document Type: Article

References (30)

1. Risk factors for progression of visual field abnormalities in normal tension glaucoma. Collaborative normal tension glaucoma study group. Am J Ophthalmol 2001;131:699-708
2. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72 (Pubitemid 350016362)
3. The ocular hypertension treatment study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of POAG. Arch Ophthalmol 2002;120:701-3
4. European glaucoma prevention study. Development of primary open angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-19
5. AGIS investigators. The advanced glaucoma intervention study (AGIS):14. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophtalmol 2002;134:499-512
6. EGS. Terminology and guidelines for glaucoma. Dogma ed. 3rd edition. Savona, Italy; 2008. p. 12-13
7. Framptom JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution. A review of its use in the treatment of glaucoma and ocular hypertension. drugs aging 2006;23:977-95
8. Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol combination study group. Ophthalmology 1998;105:1952-9 (Pubitemid 28509739)
9. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol study group. Ophthalmology 1998;105:1945-51 (Pubitemid 28509738)
10. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International clinical equivalence study group. Br J Ophthalmol 1998;82:1249-53 (Pubitemid 28524116)
11. Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-timolol study group. Ophthalmology 1998;105:1936-44 (Pubitemid 28509737)
12. Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle in glaucoma. Drugs Aging 2000;17:477-96 (Pubitemid 32102730)
13. Jampel HD, Schwartz GF, Robin AL, Abrams DA. Patient preferences for eye drop characteristics. A willingness to pay analysis. Arch Ophthalmol 2003;121:540-6 (Pubitemid 36427641)
14. Hollo G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacot 1009;10:2015-24
15. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/ timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
16. Vold SD, Evans RM, Stewart RH, et al.; the Brinzolamide/Timolol Comfort Study Group. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2008;24:601-5
17. TM (brinzolamide/timolol fixed combination) vs cosopt® (dorzolamide/ timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmol 2008;2:623-8
18. Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea 2000;19:477-82 (Pubitemid 30460884)
19. Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessment and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998;17:38-56 (Pubitemid 28047008)
20. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-9
21. Lee BL, Gutierrez P, Gordon M, et al. The glaucoma symptom scale-a brief index of glaucoma-specific symptoms. Arch Ophthalmol 1998;116:861-6
22. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000;118:615-21 (Pubitemid 30327337)
23. Rossi GCM, Tinelli C, Pasinetti GM, et al. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol 2009;4:572-9
24. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure -lowering medications. Cornea 2010;29:618-21
25. Report of the International Dry Eye WorkShop (DEWS). The epidemiology of dry eye disease. Ocular Surf 2007;5:27-41
26. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61 (Pubitemid 37315288)
27. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;23:762-70 (Pubitemid 39447304)
28. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
29. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8 (Pubitemid 37237370)
30. Zimmerman TJ, Stewart WC. For the Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 2003;19:405-15. (Pubitemid 37321343)